/

Società

In

Non verificato

Incyte

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

115 comunicati stampa

Guarda tutti i comunicati

01/09/2026

Web e Social Network

Eventi

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

Incyte to Present at Upcoming Investor Conferences

Fonte

Emittente

1.00

0

29/07/2026

Industria

Igiene alimentare

Salute

Medicina - Varie

Sanità

Farmaceutica

Biotecnologia

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Fonte

Emittente

1.00

0

28/07/2026

Web e Social Network

Telefonia e Varie

Mercato azionario

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Fonte

Emittente

1.00

0

17/07/2026

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Eventi

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Fonte

Emittente

1.00

0

13/07/2026

Eventi

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Fonte

Emittente

1.00

0

08/07/2026

Biotecnologia

Farmaceutica

Salute

Oncologia

Web e Social Network

Telefonia e Varie

Finanza

Mercato azionario

Incyte to Report Second Quarter Financial Results

Fonte

Emittente

1.00

0

06/07/2026

Mercato azionario

Biotecnologia

Farmaceutica

Salute

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Fonte

Emittente

1.00

0

26/06/2026

Industria

Oncologia

Salute

Medicina - Varie

Sanità

Farmaceutica

Biotecnologia

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Fonte

Emittente

1.00

0

13/06/2026

Eventi

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Fonte

Emittente

1.00

0

13/06/2026

Eventi

Oncologia

Igiene alimentare

Salute

Medicina - Varie

Farmaceutica

Biotecnologia

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0